Course Experts: Sandra Savaya, PharmD

Course Description: This course reviews the background information and pathophysiology of chronic lymphocytic leukemia (CLL), compares Bruton tyrosine kinase (BTK) inhibitors for CLL, and outlines the future of CLL treatment using new therapies.

[DFCI_KEYWORDS] Chronic Lymphocytic Leukemia (CLL), Bruton’s Tyrosine Kinase (BTK) Inhibitors, Pathophysiology, Prognostic Markers, Genetic Markers, Cytogenetics, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Lymphocytes, Lymphadenopathy, Venetoclax, Obinutuzumab, Rituximab, Fludarabine, Bendamustine, Antiplatelet, Anticoagulation, Leukocytosis